Millennium Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $43.3M | Buy |
96,900
+37,400
| +63% | +$17.4M | 0.02% | 932 |
|
|
2025
Q4 | $27M | Buy |
59,500
+9,400
| +19% | +$4.05M | 0.01% | 1280 |
|
|
2025
Q3 | $19.6M | Buy |
50,100
+10,200
| +26% | +$4.26M | 0.01% | 1685 |
|
|
2025
Q2 | $17.8M | Sell |
39,900
-40,000
| -50% | -$18.4M | 0.01% | 1700 |
|
|
2025
Q1 | $38.7M | Buy |
79,900
+25,400
| +47% | +$11.8M | 0.02% | 948 |
|
|
2024
Q4 | $21.9M | Buy |
54,500
+44,300
| +434% | +$20.5M | 0.01% | 1446 |
|
|
2024
Q3 | $4.74M | Sell |
10,200
-49,200
| -83% | -$23.6M | ﹤0.01% | 2890 |
|
|
2024
Q2 | $27.8M | Buy |
59,400
+20,700
| +53% | +$8.98M | 0.01% | 1220 |
|
|
2024
Q1 | $16.2M | Sell |
38,700
-67,100
| -63% | -$28.4M | 0.01% | 1732 |
|
|
2023
Q4 | $43M | Sell |
105,800
-16,000
| -13% | -$5.91M | 0.02% | 903 |
|
|
2023
Q3 | $42.4M | Buy |
121,800
+54,600
| +81% | +$19.1M | 0.02% | 821 |
|
|
2023
Q2 | $23.6M | Sell |
67,200
-69,100
| -51% | -$23.3M | 0.01% | 1259 |
|
|
2023
Q1 | $42.9M | Buy |
136,300
+52,100
| +62% | +$15.6M | 0.02% | 797 |
|
|
2022
Q4 | $24.3M | Buy |
84,200
+29,700
| +54% | +$9.05M | 0.01% | 1276 |
|
|
2022
Q3 | $15.8M | Sell |
54,500
-75,400
| -58% | -$21.7M | 0.01% | 1596 |
|
|
2022
Q2 | $36.6M | Buy |
129,900
+21,000
| +19% | +$5.62M | 0.02% | 834 |
|
|
2022
Q1 | $28.4M | Buy |
108,900
+45,500
| +72% | +$10.8M | 0.02% | 1064 |
|
|
2021
Q4 | $13.9M | Sell |
63,400
-28,500
| -31% | -$5.54M | 0.01% | 1798 |
|
|
2021
Q3 | $16.7M | Sell |
91,900
-16,400
| -15% | -$3.2M | 0.01% | 1494 |
|
|
2021
Q2 | $21.8M | Sell |
108,300
-139,800
| -56% | -$29.2M | 0.01% | 1123 |
|
|
2021
Q1 | $53.3M | Buy |
248,100
+212,400
| +595% | +$46.7M | 0.04% | 459 |
|
|
2020
Q4 | $8.44M | Buy |
35,700
+2,200
| +7% | +$505K | 0.01% | 1925 |
|
|
2020
Q3 | $9.12K | Buy |
33,500
+6,100
| +22% | +$1.68M | 0.01% | 1343 |
|
|
2020
Q2 | $7.95M | Sell |
27,400
-18,900
| -41% | -$5.12M | 0.01% | 1376 |
|
|
2020
Q1 | $11M | Buy |
+46,300
| New | +$10.6M | 0.02% | 794 |
|
|
2017
Q2 | – | Sell |
-205,000
| Closed | -$22.4M | – | 3905 |
|
|
2017
Q1 | $22.4M | Buy |
+205,000
| New | +$18M | 0.04% | 612 |
|
|
2016
Q3 | – | Sell |
-75,000
| Closed | -$6.45M | – | 3645 |
|
|
2016
Q2 | $6.45M | Sell |
75,000
-155,000
| -67% | -$13.4M | 0.01% | 1110 |
|
|
2016
Q1 | $18.3M | Buy |
230,000
+80,000
| +53% | +$7.24M | 0.05% | 526 |
|
|
2015
Q4 | $18.9M | Hold |
150,000
| – | – | 0.04% | 601 |
|
|
2015
Q3 | $15.6M | Buy |
+150,000
| New | +$19.3M | 0.03% | 684 |
|
|
2015
Q1 | – | Sell |
-100,000
| Closed | -$11.9M | – | 4151 |
|
|
2014
Q4 | $11.9M | Sell |
100,000
-200,000
| -67% | -$22.5M | 0.03% | 887 |
|
|
2014
Q3 | $33.7M | Sell |
300,000
-237,500
| -44% | -$22.6M | 0.09% | 278 |
|
|
2014
Q2 | $50.9M | Sell |
537,500
-89,000
| -14% | -$6.24M | 0.14% | 140 |
|
|
2014
Q1 | $44.3M | Buy |
626,500
+449,300
| +254% | +$35.6M | 0.13% | 177 |
|
|
2013
Q4 | $13.2M | Buy |
177,200
+56,200
| +46% | +$3.91M | 0.04% | 537 |
|
|
2013
Q3 | $9.17M | Buy |
+121,000
| New | +$9.63M | 0.03% | 732 |
|
Other funds holding VRTX
VCM
VPM
Millennium Management's VRTX Position: Q1 2026 in Review
Millennium Management reduced its Vertex Pharmaceuticals (VRTX) stake by 92% in Q1 2026, selling an estimated $156M and leaving 30,823 shares worth $13.8M. The position accounts for 0.01% of the portfolio, ranked #1864.
Millennium Management first reported a position in VRTX in Q2 2013 and has held it in 51 quarters since. The position peaked at $375M in Q2 2023. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Millennium Management held 30,823 shares of Vertex Pharmaceuticals worth $13.8M as of Q1 2026.
- Millennium Management sold 334,841 Vertex Pharmaceuticals shares in Q1 2026, an estimated $156M.
- Vertex Pharmaceuticals made up 0.01% of Millennium Management's portfolio in Q1 2026, its #1864 holding.
- Millennium Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 51 quarters since.
- Millennium Management's Vertex Pharmaceuticals position peaked at $375M in Q2 2023.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.